Hikal
Drug Manufacturers - Specialty & Generic · HIKAL
Small CapHealthcareMature Stable
Sameer Hiremath
Managing Director · Pragmatic
Company DNA
Hierarchical
About
Hikal is a Small Cap company in the Healthcare sector, listed on NSE as HIKAL. With a market cap of ₹2K Cr and revenue of ₹2K Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Long-established chemical and pharmaceutical player with traditional family-led oversight of operations. Its strategic mandate: Modernizing legacy manufacturing processes and supply chains in the pharma sector is critical for sustaining long-term margins.
FAQ
What kind of company is Hikal?
Hikal is a Small Cap Healthcare company (HIKAL) in the Mature Stable phase with a market cap of ₹2K Cr. It is classified as Hierarchical in culture.
What is Hikal's culture and work environment like?
Hikal has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Long-established chemical and pharmaceutical player with traditional family-led oversight of operations.
Who leads Hikal?
Hikal is led by Sameer Hiremath (Managing Director), a Pragmatic leader with 21 years of experience.
What are Hikal's financials?
Hikal reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of -1.4%. Operating margin: 10.6%. Market cap: ₹2K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTechnical-Expert
LifecycleMature Stable
Long-established chemical and pharmaceutical player with traditional family-led oversight of operations.
Mandate
Modernizing legacy manufacturing processes and supply chains in the pharma sector is critical for sustaining long-term margins.
Modernizing legacy manufacturing processes and supply chains in the pharma sector is critical for sustaining long-term margins.
Financials
Revenue FY25₹2K Cr
PAT FY25₹91 Cr
Rev CAGR 5Y-1.4%
OPM10.6%
NPM4.9%
ROE7.2%
ROCE11.2%
P/E—
Fwd P/E21.3
P/B1.8
D/E57.2
Mkt Cap₹2K Cr
Promoter69.1%
Institutional7.7%
Similar Culture
Could You Lead Hikal?
Take the Genome Benchmark →